GlassScriptPhysician profile
Allen R Beecham
NPI 1578594057
$4,101.45
in general payments reported to CMS, 2019-2025
22 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $614 · 2021: $762 · 2022: $403 · 2023: $363 · 2024: $611 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,368.63 | 2019-2025 | Relistor |
| Forte Bio-Pharma LLC | $503.29 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Virtus Pharmaceuticals LLC | $360.71 | 2021-2025 | Levorphanol Tartrate |
| Collegium Pharmaceutical, INC. | $292.06 | 2019-2024 | Xtampza |
| Redhill Biopharma INC. | $252.56 | 2020-2022 | |
| Pfizer INC. | $226.67 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $172.19 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $168.41 | 2019-2022 | |
| Daiichi Sankyo INC. | $157.35 | 2019 | |
| Azurity Pharmaceuticals, INC. | $151.39 | 2023-2025 | Horizant, Horizant, Adthyza |
| Sentynl Therapeutics, INC. | $119.94 | 2019 | |
| Hikma Pharmaceuticals USA | $86.12 | 2021-2024 | Kloxxado |
| Valinor Pharma, LLC | $34.72 | 2025 | Movantik |
| Averitas Pharma INC. | $30.71 | 2025 | Qutenza |
| Horizon Therapeutics Plc | $29.58 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $28.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.49 | 2019 | |
| Almatica Pharma LLC | $23.40 | 2021 | |
| Masimo Corporation | $21.50 | 2023 | Patient Safetynet System |
| Scilex Pharmaceuticals INC. | $18.87 | 2024 | |
| Kaleo, INC. | $16.31 | 2019 | |
| Assertio Therapeutics, INC. | $13.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Beecham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.